A Phase I/II study to evaluate AUTO3 in children and adults with acute lymphoblastic leukaemia who have previously received approved treatment(s).
- Registry ID
- EUCTR2016-004680-39
- Source registry
- EUCTR
- Status
- Completed
- Phase
- PHASE2
- Sponsor
- Autolus Limited
- Start date
- 2017-06-21
- Completion date
- 2020-05-18
- Last update
- 2026-08-16
Conditions
- Acute lymphoblastic leukaemia (ALL)
Summary
Phase I: Assess the safety and tolerability of AUTO3 AUTO3 in both paediatric and adult patients and identify the recommended Phase II dose, dosing schedule & maximum tolerated dose, where applicable. Phase II: Evaluate the anti-leukaemic effect of AUTO3 in paediatric and young adult patients (aged 1-24 years).
Locations
View on source registry